Comparison of the Efficacy and Renal Safety of Bisphosphonate Between Low-Dose/High-Frequency and High-Dose/Low-Frequency Regimens in a Late-Stage Chronic Kidney Disease Rat Model
- 15 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Calcified Tissue International
- Vol. 107 (4), 389-402
- https://doi.org/10.1007/s00223-020-00723-1
Abstract
The efficacy and renal safety of low-dose/high-frequency (LDHF) dosing and high-dose/low-frequency (HDLF) dosing of bisphosphonates (BPs) are comparable in patients with normal kidney function but might be different in patients with late-stage chronic kidney disease (CKD). This study aimed to compare the efficacy and renal safety of two different dosage regimens of a BP, alendronate (ALN), in stage 4 CKD using a rat model. Male, 10-week-old Sprague–Dawley rats were subjected to either 5/6 nephrectomy or sham surgery. The animals received subcutaneous administration of vehicle (daily) or ALN in LDHF dosage regimen (LDHF-ALN: 0.05 mg/kg/day) or HDLF dosage regimen (HDLF-ALN: 0.70 mg/kg/2 weeks). Medications commenced at 20 weeks of age and continued for 10 weeks. Micro-computed tomography, histological analysis, infrared spectroscopic imaging, and serum and urine assays were performed to examine the efficacy and renal safety of the ALN regimens. Both LDHF-ALN and HDLF-ALN increased bone mass, improved micro-structure, and enhanced mechanical properties, without causing further renal impairment in CKD rats. Histologically, however, HDLF-ALN more efficiently suppressed bone turnover, leading to more mineralized trabecular bone, than LDHF-ALN in CKD rats, whereas such differences between LDHF-ALN and HDLF-ALN were not observed in sham rats. Both LDHF-ALN and HDLF-ALN showed therapeutic effects on high bone turnover osteoporosis in CKD stage 4 rats without causing further renal impairment. However, as HDLF-ALN more efficiently suppressed bone turnover than LDHF-ALN in late-stage CKD, HDLF-ALN might be more appropriate than LDHF-ALN for fracture prevention in high bone turnover osteoporosis patients with late-stage CKD.Keywords
Funding Information
- Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists B (JP17K16670)
This publication has 45 references indexed in Scilit:
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature CommitteeJournal of Bone and Mineral Research, 2012
- Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failureActa Pharmacologica Sinica, 2012
- Vitamin D Therapy in Chronic Kidney Disease and End Stage Renal DiseaseClinical Journal of the American Society of Nephrology, 2012
- Phosphate Metabolism in CKD Stages 3–5: Dietary and Pharmacological ControlInternational Journal of Nephrology, 2011
- Mineral maturity and crystallinity index are distinct characteristics of bone mineralJournal of Bone and Mineral Metabolism, 2010
- Frailty and Risk of Falls, Fracture, and Mortality in Older Women: The Study of Osteoporotic FracturesThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2007
- FT-IR imaging of native and tissue-engineered bone and cartilageBiomaterials, 2007
- Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical TrialsJournal of Bone and Mineral Research, 2005
- Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJournal of Bone and Mineral Metabolism, 2005
- True StrengthJournal of Bone and Mineral Research, 2000